Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation

详细信息    查看全文

• 作者：Ying Chen (1) (2) (3)
  Lei Zhang (1) (2) (3)
  Quan Hao (1) (2) (3)
  
• 关键词：Ovarian cancer ; MicroRNA ; Biomarker
• 刊名：Cancer Cell International
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：13
• 期：1
• 全文大小：262KB
• 参考文献：1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. / CA Cancer J Clin 2012, 62:10鈥?9. CrossRef
  2. Coticchia CM, Yang J, Moses MA: Ovarian cancer biomarkers: current options and future promise. / J Natl Compr Canc Netw 2008, 6:795鈥?02.
  3. Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D, Obermair A: Differentiating Stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. / Gynecol Oncol 2013, 129:467鈥?1. CrossRef
  4. Yang N, Coukos G, Zhang L: MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. / Int J Cancer 2008, 122:963鈥?. CrossRef
  5. Slack FJ, Weidhaas JB: MicroRNA in cancer prognosis. / N Engl J Med 2008, 359:2720鈥?. CrossRef
  6. Hede K: Small RNAs are raising big expectations. / J Natl Cancer Inst 2009, 101:840鈥?. CrossRef
  7. Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G, An HJ: Deregulation of miR-519a, 153, and 485鈥?p and its clinicopathological relevance in ovarian epithelial tumours. / Histopathology 2010, 57:734鈥?3. CrossRef
  8. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Butzow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. / Proc Natl Acad Sci U S A 2008, 105:7004鈥?. CrossRef
  9. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S: MicroRNA expression profiles in serous ovarian carcinoma. / Clin Cancer Res 2008, 14:2690鈥?. CrossRef
  10. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Menard S, Croce CM: MicroRNA signatures in human ovarian cancer. / Cancer Res 2007, 67:8699鈥?07. CrossRef
  11. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih I, Zhang Y, Wood WR, Becker KG, Morin PJ: MicroRNA expression and identification of putative miRNA targets in ovarian cancer. / PLoS One 2008, 3:e2436. CrossRef
  12. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. / Cancer Res 2008, 68:425鈥?3. CrossRef
  13. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M: Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. / PLoS One 2009, 4:e5311. CrossRef
  14. Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, Wang TH, Lai CH: Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. / Oncogene 2012, 31:764鈥?5. CrossRef
  15. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. / Gynecol Oncol 2009, 112:55鈥?. CrossRef
  16. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'Incalci M: Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. / Lancet Oncol 2011, 12:273鈥?5. CrossRef
  17. Peng DX, Luo M, Qiu LW, He YL, Wang XF: Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. / Oncol Rep 2012, 27:1238鈥?4.
  18. Griffith OL, Melck A, Jones SJ, Wiseman SM: Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. / J Clin Oncol 2006, 24:5043鈥?1. CrossRef
  19. Chan SK, Griffith OL, Tai IT, Jones SJ: Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. / Cancer Epidemiol Biomarkers Prev 2008, 17:543鈥?2. CrossRef
  20. Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H: Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. / Int J Cancer 2012, 130:2077鈥?7. CrossRef
  21. Guan P, Yin Z, Li X, Wu W, Zhou B: Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. / J Exp Clin Cancer Res 2012, 31:54. CrossRef
  22. Kim SW, Kim JW, Kim YT, Kim JH, Kim S, Yoon BS, Nam EJ, Kim HY: Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease. / Genes Chromosomes Cancer 2007, 46:1鈥?. CrossRef
  23. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. / Gastroenterology 2006, 130:2113鈥?9. CrossRef
  24. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, Anderson ML, Matzuk MM: A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. / Mol Endocrinol 2010, 24:447鈥?3. CrossRef
  25. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. / Clin Cancer Res 2009, 15:5404鈥?3. CrossRef
  26. Sun J, Chen Z, Tan X, Zhou F, Tan F, Gao Y, Sun N, Xu X, Shao K, He J: MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. / Med Oncol 2013, 30:411. CrossRef
  
• 作者单位：Ying Chen (1) (2) (3)
  Lei Zhang (1) (2) (3)
  Quan Hao (1) (2) (3)
  
  1. Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin, 300060, China
  2. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
  3. National Clinical Research Centre of Cancer, Tianjin, China
  

文摘

Despite advances in detection and therapy, epithelial ovarian cancer (EOC) still represents the most lethal gynecologic malignancy in women worldwide. The high mortality of EOC is mainly due to late-stage diagnosis for more than 70% of patients. There is an urgent need to search for specific and sensitive biomarkers for early diagnosis of EOC. Recently, the cumulative data indicated an essential role for microRNA (miRNA), a class of small non-coding RNAs targeting multiple mRNAs and triggering translation repression and/or RNA degradation, in ovarian caner carcinogenesis and progression. Here, we reviewed the published miRNA expression profiling studies that compared the miRNA expression profiles between EOC tissues or cell lines and normal ovarian tissues or benign ovarian tumor or human primary cultured ovarian surface epithelial cells. A miRNA ranking system that takes the number of comparisons in agreement and direction of differential expression into the consideration was devised and used. Finally, five promising differentially miRNAs (miR-200a, miR-100, miR-141, miR-200b, and miR-200c) were reported with the consistent direction in four or more studies. MiR-200a, miR-200b, miR-200c, and miR-141, all of them belong to miR-200 family, were reported with consistently up-regulated in at least 4 studies, whereas miR-100 was reported with down-regulated in 4 studies. Furthermore, we validated these miRNAs in a clinical setting using qRT-PCR and their dysregulations in EOC tissues confirmed the findings. Conclusively, the five most consistently expressed miRNAs might provide some clues of the potential biomarkers in EOC. Further mechanistic and precise validation studies are needed for their clinical significances and roles in the progression of EOC.